ACE2 protein protects against severe COVID-19 in women, study shows
According to new research, because women have two copies of the ACE2 protein, they are less likely to suffer from severe COVID-19, unlike men who have one copy.
List view / Grid view
According to new research, because women have two copies of the ACE2 protein, they are less likely to suffer from severe COVID-19, unlike men who have one copy.
Scientists have found that the RFWD3 protein could play a role in recruiting DNA key repair and signalling factors, impacting chemotherapy.
By combining natural killer cells with a new molecule called Sialyl-Lewis X, researchers were able to treat lymphoma in mice.
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.
Researchers engineered the Disque Platform, a high-fidelity culture system, to enable them to screen drugs able to promote β cell proliferation.
According to researchers, an interaction between host microRNA and SARS-CoV-2 could be responsible for the range of disease severities.
Cancer researchers have created a new class of drugs to selectively target and destroy myeloid leukaemia cells with TET gene mutations.
Researchers have found that spermidine can ramp up autophagy and boost T-cell function, potentially increasing the protective effects of vaccines in older adults.
Opaganib reduced blood clot length and weight in a pre-clinical model of Acute Respiratory Distress Syndrome (ARDS).
Scientists have created a drug discovery platform that enables the discovery and optimisation of RNA-targeting compounds.
Using CRISPR-Cas9, scientists have developed a new method for generating mouse lines for vaccine research in just a few weeks.
Scientists have created a prognostic classification model which uses biomarkers to help predict an individual’s risk of developing severe COVID-19 symptoms.
UK Health Secretary Matt Hancock has said there is a mutated form of SARS-CoV-2 that may be causing a rise in infections in South East England.
Scientists have identified a new family of biosynthetic genes in lichens with unknown functions, which could produce new molecules for the pharmaceutical industry.
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.